Analysts Offer Predictions for Aldeyra Therapeutics, Inc’s Q3 2023 Earnings (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q3 2023 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued on Friday, March 10th. Jefferies Financial Group analyst K. Shi forecasts that the biotechnology company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($1.38) per share.

ALDX has been the topic of a number of other reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Aldeyra Therapeutics in a report on Wednesday, March 1st. StockNews.com upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, November 14th. Finally, Citigroup boosted their price target on Aldeyra Therapeutics from $23.00 to $28.00 in a report on Friday.

Aldeyra Therapeutics Stock Performance

Shares of Aldeyra Therapeutics stock opened at $7.18 on Monday. The firm has a market cap of $420.46 million, a price-to-earnings ratio of -6.77 and a beta of 1.07. The stock’s 50-day moving average is $6.65 and its 200-day moving average is $6.17. Aldeyra Therapeutics has a one year low of $2.36 and a one year high of $8.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.83 and a quick ratio of 7.83.

Institutional Trading of Aldeyra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Knoll Capital Management LLC raised its holdings in Aldeyra Therapeutics by 24.9% during the third quarter. Knoll Capital Management LLC now owns 1,877,305 shares of the biotechnology company’s stock worth $10,025,000 after acquiring an additional 374,845 shares in the last quarter. Woodstock Corp increased its position in Aldeyra Therapeutics by 23.3% during the third quarter. Woodstock Corp now owns 129,179 shares of the biotechnology company’s stock worth $690,000 after buying an additional 24,445 shares during the last quarter. Virtu Financial LLC acquired a new position in Aldeyra Therapeutics during the third quarter worth approximately $99,000. International Assets Investment Management LLC increased its position in Aldeyra Therapeutics by 4.8% during the second quarter. International Assets Investment Management LLC now owns 59,875 shares of the biotechnology company’s stock worth $239,000 after buying an additional 2,750 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in Aldeyra Therapeutics during the third quarter worth approximately $267,000. Institutional investors own 63.11% of the company’s stock.

About Aldeyra Therapeutics

(Get Rating)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.